Summit Therapeutics Inc. announced that it has determined its first two indications in non-small cell lung cancer (NSCLC) in which to pursue Phase III clinical trials for its innovative, potential first-in-class bispecific antibody, ivonescimab. Summit has held multiple meetings with the US Food and Drug Administration (FDA) during the first quarter of 2023 regarding its planned Phase III clinical program and incorporated this feedback accordingly. The company plan to initiate clinical studies in the following indications: Ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)- mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (TKI) (HARMONi) (HARMONi).
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.445 USD | -1.00% | -6.90% | +70.50% |
May. 07 | Citigroup Starts Summit Therapeutics With Buy Rating, $7 Price Target | MT |
May. 01 | Transcript : Summit Therapeutics Inc., Q1 2024 Earnings Call, May 01, 2024 |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+70.50% | 3.15B | |
+7.31% | 113B | |
+11.17% | 106B | |
+0.41% | 22.27B | |
-12.00% | 22.22B | |
-5.99% | 19.43B | |
-37.85% | 17.87B | |
-6.21% | 17.24B | |
+7.03% | 14.29B | |
+34.80% | 12.52B |
- Stock Market
- Equities
- SMMT Stock
- News Summit Therapeutics Inc.
- Summit Therapeutics Announces Initial Indications for Clinical Trials for Ivonescimab